Abstract PS14-01: Radium-223 in women with HR-positive bone-metastatic breast cancer receiving endocrine therapy: International phase 2, randomized, double-blind, placebo-controlled trial
Robert E. Coleman(University of Sheffield), Hope S. Rugo(City of Hope), Sung‐Bae Kim(Ulsan College), Joohyuk Sohn(Yonsei University), David Kiesl(Kepler Universitätsklinikum), Manuel Ramos(Universidade do Porto), Deise Uema(Daiichi Sankyo (United States)), Iryna Kuchuk(University of Ottawa), Rui Li(Wannan Medical College), Georgeta Fried(Roche (Switzerland)), Volker Jean Wagner(Bayer (Switzerland)), J. Siegel(Bayer (United States))
Cited by 3
Related Papers
Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
|New England Journal of Medicine|2013|3.3k
Palbociclib and Letrozole in Advanced Breast Cancer
|New England Journal of Medicine|2016|2.9k
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k